Key result
Fenofibrate reduces mitochondrial damage in diabetic cardiomyopathy models by promoting EHHADH expression.
Why the study?
The role of mitochondria-related gene EHHADH in diabetic cardiomyopathy and its potential protective effects were not well understood.
Population
In vivo and in vitro diabetic cardiomyopathy models including H9C2 cells treated with high glucose and palmitic acid
Comparison
EHHADH knockdown and Fenofibrate treatment vs control models
Design
Preclinical experimental study
Authors
Loading...
Hypothesis-generating for EHHADH-targeted therapy in diabetic cardiomyopathy; clinical trials needed before any practice implications.
EHHADH exerts a protective effect in diabetic cardiomyopathy by reducing mitochondrial damage, oxidative stress, and cardiomyocyte apoptosis, which can be promoted by fenofibrate.
Sun et al. (2026) studied Diabetic cardiomyopathy. EHHADH knockdown and Fenofibrate was evaluated on Mitochondrial damage, oxidative stress, lipid accumulation, and cardiomyocyte apoptosis. EHHADH knockdown aggravated apoptosis and lipid accumulation in diabetic cardiomyopathy models, while Fenofibrate promoted EHHADH expression and reduced mitochondrial damage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: